

Angiogene Incorporated

[View the current Angiogene Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/806-Angiogene+Incorporated.html)
(<http://www.bioportfolio.com/biocorporate/806-Angiogene+Incorporated.html>)

Contact Details:

1851 Sherbrooke E. Suite 704
Montreal
Quebec
H2K 4L5
United Kingdom

Tel: (514) 596-1111
Fax: (514) 596-1119
Email:

Antiproliferative Therapeutics Drug Discovery Cardiovascular Diseases Oncology Radio

Recent Publications by Angiogene Incorporated:



- [Exploiting the tumor microenvironment in the development of targeted cancer gene therapy.](#)
*The future success of cancer gene therapy is critically dependent upon the...*2nd April, 2009
Angiogene Pharmaceuticals Ltd, The Magdalen Centre, Oxford, UK.- *Cancer Gene Ther.* 2009 Mar;16(3):279-90. Epub 2008 Sep 26. ([DOI Direct Link](#))
- [32P-oligodeoxynucleotide-coated coils to prevent arterial recanalization after embolization.](#)
*BACKGROUND AND PURPOSE: Endovascular treatment of aneurysms with coils, a...*5th October, 2004
Angiogene Inc., Montreal, Quebec, Canada.- *AJNR Am J Neuroradiol.* 2004 Jun-Jul;25(6):1062-6.
- [ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.](#)
*Physiological differences between tumor and normal vasculature provide a...*29th January, 2003
Angiogene Pharmaceuticals Ltd., Oxford Science Park, Oxford, United- *Cancer Res.* 2002 Dec 15;62(24):7247-53.
- [Enhancement of vascular targeting by inhibitors of nitric oxide synthase.](#)
*PURPOSE: This study investigates the enhancement of the vascular targeting...*3rd January, 2003
Angiogene Pharmaceuticals- *Int J Radiat Oncol Biol Phys.* 2002 Dec 1;54(5):1532-6.

Press Releases on Angiogene Incorporated:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>
Spherix Announces the Closing of \$6.3 Million Registered Direct Offering	19th November, 2009	Spherix Incorporated	<i>BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting</i>
Spherix Announces Results of Annual Shareholders Meeting	19th November, 2009	Spherix Incorporated	<i>-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants</i>
Give Your Pooch the Gift of Wisdom This Holiday	19th November, 2009	Mars Veterinary	<i>ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend</i>

Angiogene Incorporated Patents:



- 7608698- [Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions](#)

- 6339071- [Antisense oligonucleotide modulating cyclin E gene expression and therapeutic uses thereof](#)
- 6423753- [Use of colchicol derivatives as vascular damaging agents](#)
- 6626928- [Occlusion device for treating aneurysm and use therefor](#)
- 6645950- [Benzimidazole vascular damaging agents](#)
- 6720323- [Colchicol derivatives as angiogenesis inhibitors](#)
- 6846925- [Colchicol derivatives as angiogenesis inhibitors](#)
- 7081469- [Benzimidazole vascular damaging agents](#)
- 7087627- [Combinations for the treatment of diseases involving angiogenesis](#)
- 7105501- [Compositions with vascular damaging activity](#)
- 7135502- [Colchicol derivatives as vascular damaging agents](#)
- 7265136- [Substituted stilbene compounds with vascular damaging activity](#)
- 5821354- [Radiolabeled DNA oligonucleotide and method of preparation](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

